Back to Search
GERALD SHAPIRO, PHARMD
PHARMD
Pharmacist
NPI: 1669458204Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
24377(CA)
Research & Publications (20)
A randomized trial of a representational intervention to decrease cancer pain (RIDcancerPain).
PMID 18230015·Health Psychol·2008
2-rct
Cyclin-dependent kinase pathways as targets for cancer treatment.
PMID 16603719·J Clin Oncol·2006
6-review
Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
PMID 15217973·Clin Cancer Res·2004
6-review
Sequence-specific targeting of two bases on both DNA strands by the somatic hypermutation mechanism.
PMID 12943801·Mol Immunol·2003
7-preclinical
Evolution of Ig DNA sequence to target specific base positions within codons for somatic hypermutation.
PMID 11859119·J Immunol·2002
7-preclinical
DNA target motifs of somatic mutagenesis in antibody genes.
PMID 12498382·Crit Rev Immunol·2002
6-review
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
PMID 11410495·Clin Cancer Res·2001
3-trial
The physiology of p16(INK4A)-mediated G1 proliferative arrest.
PMID 11325039·Cell Biochem Biophys·2000
6-review
Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole.
PMID 19679174·Brain Res Bull·2010
7-preclinical
Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients.
PMID 19192466·J Clin Psychiatry·2009
4-observational
Clinical diagnosis of sleep apnea based on single night of polysomnography vs. two nights of polysomnography.
PMID 19067010·Sleep Breath·2009
8-other
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
PMID 19122144·Proc Natl Acad Sci U S A·2009
7-preclinical
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
PMID 19451690·J Clin Invest·2009
7-preclinical
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
PMID 19318484·Clin Cancer Res·2009
3-trial
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
PMID 19079597·PLoS One·2008
7-preclinical
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
PMID 18758305·J Thorac Oncol·2008
3-trial
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
PMID 18632637·Cancer Res·2008
7-preclinical
Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.
PMID 18621626·Clin Lung Cancer·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 444 S FLOWER ST, 100
LOS ANGELES, CA 90071 - Phone
- (213) 612-4300
Quick Facts
- NPI
- 1669458204
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile